Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson (JNJ.N) announced on Wednesday a significant move towards resolving ongoing litigation over its baby powder and other talc products, with a proposed settlement amounting to $6.475 billion. This substantial figure is aimed at settling tens of thousands of lawsuits alleging that the company's talc products contain asbestos and could cause ovarian cancer.

Johnson & Johnson proposes $6.475 billion settlement in talc lawsuits

MONTGOMERY, Ala.--(BUSINESS WIRE)--A coalition of attorneys representing tens of thousands of women harmed by Johnson & Johnson's talc-based powder products is challenging J&J's attempt to weaponize unrelated claims in exchange for votes on a payment plan that would cheat victims legitimately harmed by talc. It's a shocking new legal strategy that could strip consumers of their constitutional rights and allow major corporations to evade responsibility for the harm caused by defective pr.

Beasley Allen Law Firm: Attorneys for Women Harmed by Johnson & Johnson's Talcum Powder Resist Company's Attempt to Stuff Ballot Box in Unprecedented Third Attempted Bankruptcy

Deal would resolve tens of thousands of lawsuits alleging company's baby powder causes ovarian cancer

Johnson & Johnson proposes $6.5bn settlement of talc cancer lawsuits

Johnson & Johnson JNJ, -1.52% unveiled its latest plan to settle ovarian cancer talc claims with the news of a consensual “prepackaged” reorganization of its LTL Management LLC unit, which manages the legal wrangling. The plan is expected to resolve 99.75% of all pending talc lawsuits against the company and its units in the U.S., it said in a statement.

Johnson & Johnson unveils latest plan to settle ovarian cancer talc claims

Johnson & Johnson is moving forward with a $6.475 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products contain asbestos and cause ovarian cancer, the company said Wednesday in a statement.

J&J advances $6.475 billion settlement of talc cancer lawsuits

Johnson & Johnson will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced a proposed Plan of Reorganization (the “Plan”) by its subsidiary, LLT Management LLC ("LLT"), for the comprehensive and final resolution of all current and future claims related to ovarian cancer arising from cosmetic talc litigation against it and its affiliates in the United States. “The Plan is the culmination of our consensual resolution strategy that we announced last October,” said Erik.

Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization

Cosmos Holdings

Innovage Holding Corp

The healthcare industry has experienced unprecedented growth in recent years due to the global pandemic. However, as COVID-19 began to ease, the immense growth of the healthcare industry is expected to slow down.

Stock Market Crash Warning: Don't Get Caught Holding These 3 Healthcare Stocks

Oracle

Occidental Petroleum

When the biggest names on Wall Street make an investment decision, the world listens. As the first quarter of 2024 comes to a close, SEC 13-F filings are coming in hot, showing investors where some of the biggest fund managers are finding investing opportunities despite market indexes hovering near all-time highs.

3 Stocks Mega Investors Are Buying

ASML Hld

Procter & Gamble

If you're searching for stocks to outperform the S&P 500, look no further. Some stocks are more solid than others against market downturns and macro-economic uncertainty and have high chances of beating the S&P 500 index.

Slump Survivors: 3 Stocks That Will Outlast the S&P 500 Downturn

Bristol-Myers

The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.

Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug price negotiations

A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

J&J, Bristol Myers lose challenges to US drug price negotiation program

Align Technology

Intuitive Surgical

Undoubtedly, investors seem to have a new appetite for next-level revenue growth. Generative AI, GLP-1 weight-loss drugs and other breakthrough innovations (I'm not sure if the metaverse qualifies right now) seek to expand in some pretty massive markets.

Cutting Edge Picks: 3 Med Tech Stocks With Room to Run

Johnson & Johnson has a higher credit rating than the U.S. Federal Government. The healthcare giant is in the elite class of Dividend Kings.

Johnson & Johnson Is a King of Dividend Safety

Biogen

British American Tobacco

Healthcare Realty Trust Inc

Hershey

NIKE

Universal Health Realty Income Trust

One of the best ways to keep your portfolio safe while generating consistent income is in safe, dividend-paying retirement stocks at 52-week lows. It's even better if you're buying into a reputable company that's paid out dividends for years, and is on sale.

7 Retirement Stocks to Buy at a 52-Week Low in April

Vertex Pharmaceuticals

The healthcare industry tends to do well in all types of economies. Vertex just garnered a new blockbuster approval, and more could be around the corner.

2 Top Growth Stocks to Buy Right Now and Hold Forever

AbbVie

AbbVie and Johnson & Johnson have excellent dividend track records and solid businesses. However, one of these healthcare giants has a slight edge over the other.

Better Dividend Stock: AbbVie or Johnson & Johnson?

Johnson & Johnson's business generated modest single-digit growth last quarter. The drugmaker announced it will be raising its dividend for a 62nd consecutive year.

Johnson & Johnson Stock: Buy, Sell, or Hold?

Visa

Looking for long-term stocks to buy for decades of gains requires a strategy focusing on stable, established companies with proven track records. The key to selecting long-term stocks to buy to build generational wealth is identifying companies with strong fundamentals, competitive advantages, and financial stability over time.

Generational Wealth Builders: 3 Stocks to Own for Decades of Gains

Amcor Plc

Becton, Dickinson and Co.

Coca-Cola

NextEra Energy

Exxon Mobil

Investors don't have to look far to find justification for investing in dividend aristocrats. Generally speaking, dividends are an excellent way to secure stable returns and compound one's wealth.

How Much Will $10k Invested in These Dividend Aristocrats Grow to by 2025?

Realty Income Corp

Schwab US Dividend Equity ETF

Target

T. Rowe Price Group

March is one of the lower months for SCHD for dividend payments. Realty Income has been one of my top stock buys in 2024.

Bert's March Dividend Income Summary

CVS Health

Lowe's

McDonald's

UnitedHealth Group

Recent market volatility may have many market participants buying major tech stocks on the dip, but the genuine opportunity may lie with blue chip stocks to buy on the dip. Blue-chips can be a great cornerstone for your portfolio.

7 blue chip stocks to Buy on the Dip: April 2024

MILFORD, Conn.--(BUSINESS WIRE)-- #SOC2--PBIRx, a pharmacy benefits consulting and auditing firm, sees growth from concerns over alleged fiduciary breach lawsuit against Johnson & Johnson.

PBIRx Growth Fueled by Johnson & Johnson ERISA Lawsuit

Altria

Pfizer

In the changing environment of 2024, astute investors have a plethora of options to strengthen their financial portfolios strategically by purchasing dividend stocks. These prospects result from industry titans' forward-thinking initiatives and solid performance.

News for Johnson & Johnson Stock (JNJ)